Alpha1-proteinase inhibitor augmentation therapy for severe alpha1-antitrypsin deficiency
Customize your policy alerts
Sign up for caresourcegeorgia Policy GA-MED-P-366579 alerts
Get alerted when Policy GA-MED-P-366579 changes without checking for updates manually.
Monitor payer policy activity
Coverage and prior authorization for Aralast NP, Glassia, Prolastin C, and Zemaira augmentation therapy in adults with clinically evident emphysema caused by severe alpha1-antitrypsin deficiency.
The policy history documents removal of a lower FEV1 limit and the rate-of-decline requirement in 2023.
The policy history documents addition of a liver-transplant exclusion in 2023.
The policy was updated with references on March 10, 2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.